Literature DB >> 2240186

Hearing loss--risk factor for cisplatin ototoxicity? Observations.

J D Durrant1, G Rodgers, E N Myers, J T Johnson.   

Abstract

Ototoxicity associated with cisplatin chemotherapy is well established, but opinion is split regarding the relative risk associated with preexisting hearing loss. The emerging consensus is that pretreatment loss does not increase the risk of cisplatin ototoxicity. Results from a preliminary study of a small sample from our patient population supports this consensus.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2240186

Source DB:  PubMed          Journal:  Am J Otol        ISSN: 0192-9763


  2 in total

Review 1.  Monitoring Protocols for Cochlear Toxicity.

Authors:  Sherman G Lord
Journal:  Semin Hear       Date:  2019-04-26

2.  Ototoxicity of cisplatin plus standard radiation therapy vs. accelerated radiation therapy in glioblastoma patients.

Authors:  Nicole E Marshall; Karla V Ballman; John C Michalak; Paula J Schomberg; Gary V Burton; Howard M Sandler; Terrence L Cascino; Kurt A Jaeckle; Jan C Buckner
Journal:  J Neurooncol       Date:  2006-05       Impact factor: 4.130

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.